Illumina (NASDAQ:ILMN) released its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04), Fidelity Earnings reports. Illumina had a return on equity of 24.51% and a net margin of 24.79%. The company had revenue of $867.00 million during the quarter, compared to analysts’ expectations of $865.33 million. During the same quarter in the previous year, the company earned $1.44 EPS. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. Illumina updated its FY 2019 guidance to $6.50-6.60 EPS and its FY19 guidance to $6.50-6.60 EPS.
Illumina stock opened at $293.52 on Thursday. The firm has a market cap of $43.44 billion, a PE ratio of 51.31, a price-to-earnings-growth ratio of 2.03 and a beta of 1.20. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23. Illumina has a 1-year low of $216.34 and a 1-year high of $372.61.
ILMN has been the subject of a number of research analyst reports. Morgan Stanley cut their target price on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research report on Monday, January 7th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Monday, December 31st. Deutsche Bank downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a research report on Friday, January 25th. Bank of America reiterated a “buy” rating and issued a $355.00 target price on shares of Illumina in a research report on Wednesday, January 30th. Finally, Leerink Swann upgraded shares of Illumina to an “outperform” rating and cut their target price for the stock from $380.00 to $365.00 in a research report on Wednesday, January 30th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $346.40.
TRADEMARK VIOLATION NOTICE: This story was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/02/14/illumina-ilmn-announces-earnings-results.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: What Are Treasury Bonds?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.